Serum p53 antibodies in patients affected with ulcerative colitis

被引:18
作者
Cioffi, M
Riegler, G
Vietri, MT
Pilla, P
Caserta, L
Carratù, R
Sica, V
Molinari, AM
机构
[1] Second Sch Med, Dept Gen Pathol, Naples, Italy
[2] Second Sch Med, Gastroenterol Hlth Serv, Naples, Italy
关键词
anti-p53; antibodies; colorectal cancer; ulcerative colitis;
D O I
10.1097/00054725-200409000-00016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
During tumor progression, the accumulation in genetic alterations is a fundamental characteristic of malignant cells. p53 gene is frequently mutated in human tumor. Cellular accumulation of p53 protein can initiate an immune response with generation of circulating anti-p53 antibodies. Patients with ulcerative colitis have an increased risk of developing colorectal neoplasm and, among the different genes involved in carcinogenesis, p53 may play a key role. Sera and tissues from 97 patients (M = 53, F = 44) affected with ulcerative colitis (UC) were collected. Serum anti-p53 antibodies (p53Abs) were detected in duplicate with ELISA method. Serum p53Abs were detectable in 9.3% (9/97) of patients affected with UC. In these patients, the titer of p53Ab ranged between 3.1 and 14.9 U/mL (mean, 6.6 U/mL; SD, 4.64). Serum p53Abs were undetectable in control group. With an immunoluminometric assay for the quantitative determination of p53, we found 9/97 positive samples (greater than or equal to0.69 mg/mg of total proteins). In contrast, the samples of the remaining 89 patients were found negative (less than or equal to0.30 mg/mg of total proteins). All patients that were positive for anti-p53 antibodies were also positive with p53 protein accumulation in the tissue of colonic biopsies. In UC, follow-up with colonoscopy has several advantages. The colonoscopy is not well accepted by patients, and poor patient observance has the potential to seriously devalue the technique as a screening tool, despite practical considerations of competence within endoscopy service. Serological detection of p53Abs by enzyme-linked immunosorbent assay (ELISA) is easy to perform, does not require tumor specimen, can be performed in a routine diagnostic procedure, may be used in clinical practice, and could facilitate physicians in patient monitoring. We suggest that serum p53Abs assessment, indirect marker for p53 gene mutations, and abnormally high p53 protein levels could be considered to have a potential for use as a complementary test to improve surveillance program performance.
引用
收藏
页码:606 / 611
页数:6
相关论文
共 50 条
[21]   Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer [J].
Kojima, Taiki ;
Yoshikawa, Kazuhiro ;
Matsui, Takanori ;
Kodera, Yasuhiro ;
Kojima, Hiroshi .
MOLECULAR MEDICINE REPORTS, 2009, 2 (03) :477-480
[22]   Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients [J].
Ochiai, Hiroki ;
Ohishi, Takashi ;
Osumi, Koji ;
Tokuyama, Jo ;
Urakami, Hidejirou ;
Seki, Shikou ;
Shimada, Atsushi ;
Matsui, Akira ;
Isobe, Yoh ;
Murata, Yuya ;
Endo, Takashi ;
Ishii, Yoshiyuki ;
Hasegawa, Hirotoshi ;
Matsumoto, Sumio ;
Kitagawa, Yuko .
SURGERY TODAY, 2012, 42 (02) :164-168
[23]   Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium [J].
Matsuda, K ;
Watanabe, H ;
Ajioka, Y ;
Kobayashi, M ;
Saito, H ;
Sasaki, M ;
Yasuda, K ;
Kuwabara, A ;
Nishikura, K ;
Muto, T .
JOURNAL OF GASTROENTEROLOGY, 1996, 31 (06) :860-867
[24]   p53 expression in patients with ulcerative colitis - associated with dysplasia and carcinoma: a systematic meta-analysis [J].
Xiaohong Lu ;
Yuanjie Yu ;
Shiyun Tan .
BMC Gastroenterology, 17
[25]   Clinical significance of serum p53 antibodies in oral cancer [J].
Sainger, Rachana Narendra Singh ;
Shah, Manisha Hasmukhray ;
Desai, Amisha Anil ;
Shukla, Shilin Nandubhai ;
Shah, Pankaj Manubhai ;
Telang, Shaila Dattatraya ;
Patel, Prabhudas Shankerbhai .
TUMORI JOURNAL, 2006, 92 (02) :134-139
[26]   Understanding p53 functions through p53 antibodies [J].
Sabapathy, Kanaga ;
Lane, David P. .
JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) :317-329
[27]   Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis-Associated Cancer or Dysplasia [J].
Noguchi, Tatsuki ;
Ando, Takumi ;
Emoto, Shigenobu ;
Nozawa, Hiroaki ;
Kawai, Kazushige ;
Sasaki, Kazuhito ;
Murono, Koji ;
Kishikawa, Junko ;
Ishi, Hiroaki ;
Yokoyama, Yuichiro ;
Abe, Shinya ;
Nagai, Yuzo ;
Anzai, Hiroyuki ;
Sonoda, Hirofumi ;
Hata, Keisuke ;
Sasaki, Takeshi ;
Ishihara, Soichiro .
INFLAMMATORY BOWEL DISEASES, 2022, 28 (07) :1072-1080
[28]   Mutations of p53 in morphologically non-neoplastic mucosa of long-standing ulcerative colitis [J].
Takaku, H ;
Ajioka, Y ;
Watanabe, H ;
Hashidate, H ;
Yamada, S ;
Yokoyama, J ;
Kazama, S ;
Suda, T ;
Hatakeyama, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (02) :119-126
[29]   Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma [J].
Abdelmoula-Souissi, Salma ;
Zouari, Nourane ;
Miladi-Abdenadher, Imen ;
Yaich-Kolsi, Ouhoud ;
Ayadi-Masmoudi, Ines ;
Khabir, Abdelmajid ;
Masmoudi, Hatem ;
Frikha, Mounir ;
Mokdad-Gargouri, Raja .
MOLECULAR BIOLOGY REPORTS, 2013, 40 (05) :3865-3872
[30]   Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients [J].
Morita, T ;
Tachikawa, N ;
Kumamaru, T ;
Nukui, A ;
Ikeda, H ;
Suzuki, K ;
Tokue, A .
EUROPEAN UROLOGY, 2000, 37 (01) :79-84